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Abstract 24 
Women undergoing treatment for infertility could be a sensitive subpopulation for endocrine effects 25 
of exposure to perfluorinated alkyl acids (PFAAs), persistent organic pollutants with potential 26 
endocrine activity. Women with polycystic ovarian syndrome (PCOS, n=30) and age- and BMI-matched 27 
controls (n=29) were recruited from a UK fertility clinic in 2015.  Paired serum and follicular fluid 28 
samples were collected and analysed for 13 PFAAs.  Sex steroid and thyroid hormones, metabolic 29 
markers, and serum biochemical parameters were measured and assessed for associations with serum 30 
PFAAs. Four PFAAs were detected in all serum and follicular fluid samples and concentrations in the 31 
two matrices were highly correlated (R2>0.95):  perfluorooctane sulfonate (PFOS), perfluorooctanoic 32 
acid (PFOA), perfluorohexane sulfonate (PFHxS), and perfluorononanoic acid (PFNA).  Serum PFOS was 33 
positively associated with age (p<0.05) and was higher in PCOS cases than controls (geometric mean 34 
3.9 vs. 3.1 ng/mL, p<0.05) and in women with irregular vs. regular menstrual cycles (p<0.05).  When 35 
adjusted for PCOS case status and serum albumin, serum testosterone was positively associated with 36 
PFOA, and sex hormone binding globulin was positively associated with PFOS (p<0.05); no other 37 
associations between sex steroid or thyroid hormones and PFAA concentrations were observed.  38 
Fasting glucose was significantly positively associated with PFOA, adjusted for age, PCOS status, and 39 
serum albumin (p<0.05).  Serum insulin and HbA1c were positively associated with BMI (p<0.01), but 40 
not with PFAAs. Serum PFAA concentrations can be used as surrogates for follicular fluid 41 
concentrations due to the high correlations observed.  Limited associations between serum PFAAs and 42 
sex steroid hormones and fasting glucose were observed.  Associations were modified by serum 43 
albumin, which can influence serum PFAA concentrations, and these interrelationships should be 44 
considered in assessing endocrine associations for PFAAs.   45 
 46 
Key words: polycystic ovary syndrome; IVF; PFAA, endocrine disrupting chemicals; perfluorinated alkyl 47 
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Introduction 49 
Perfluorinated alkyl acids (PFAAs; perfluorinated chemicals (PFCs)) consist of a fluorinated 50 
hydrophobic alkyl chain with a hydrophilic end group, and are used widely as surfactants in household 51 
and industrial applications such as textile treatments, food packaging, and as aqueous film-forming 52 
foams. The dominant exposure pathway for humans is diet, particularly meat and fish, and via breast 53 
milk for infants (Gebbink et al., 2015; Haug et al., 2010; Kärrman et al., 2007). PFAAs are persistent 54 
and bioaccumulative. Elimination of PFAAs depends on chain length and they sequester particularly in 55 
the liver and kidney. They are non-covalently bound to protein in serum, particularly serum albumin 56 
(Andersen et al., 2008; Bischel et al., 2010). Serum elimination half-life is approximately 3.8 and 5.4 57 
years for perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA), respectively (Li et al., 58 
2017b; Olsen et al., 2007). PFAAs can cross the placenta (Kim et al., 2011), and have been associated 59 
with adverse effects on fertility, birth outcomes, and early development in humans (Bach et al., 2015; 60 
Goudarzi et al., 2016; Lyngso et al., 2014; Olsen et al., 2009). PFOS and PFOA have intrinsic estrogenic 61 
activity and anti-estrogenic effects in vitro (Henry and Fair, 2013), and PFOS is capable of modulating 62 
steroidogenesis (Kraugerud et al., 2011). In vivo, PFAAs were associated with increased breast cancer 63 
risk in Inuit women, perhaps related to their estrogenic effects (Bonefeld-Jorgensen et al., 2011), while 64 
other studies have shown increased serum PFAAs associated with an earlier menopause, and with 65 
PFOS being inversely associated with estradiol levels (Knox et al., 2011).  Because PFAAs are eliminated 66 
via both menstruation and renal elimination, it may be difficult to assess and interpret relationships 67 
between serum PFAA concentrations and outcomes such as birth weight, which can be affected by 68 
glomerular filtration rates, or timing of menopause, which can influence PFAA levels due to decreased 69 
elimination of PFAAs post-menopause (Ruark et al., 2017; Verner et al., 2015).  70 
 71 
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders and affects 6-20% 72 
of reproductive-aged women (Bozdag et al., 2016; March et al., 2010; Teede et al., 2013; Yildiz et al., 73 
2012) with clinical manifestations of irregular menstruation, hyperandrogenism and/or polycystic 74 
ovaries (Bozdag et al., 2016; PCOS Consensus Workshop, 2004). PCOS is associated with infertility, 75 
hirsutism, and acne (Ehrmann, 2005; Norman et al., 2007). Thus, PCOS patients may be a sensitive 76 
subpopulation for compounds that alter endocrine outcomes.  The previously reported association of 77 
PFAAs with menstrual irregularity and infertility (Lyngso et al., 2014; Velez et al., 2015) may have been 78 
influenced by the inclusion of women with PCOS in the studies. The aim of the study was to examine 79 
correlation of serum and follicular fluid measures of PFAAs, and to explore the associations of PFAAs 80 
with hormonal parameters in women with and without PCOS, and undergoing fertility treatment.  81 
 82 
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Materials and Methods 83 
This prospective cohort study was performed within the Hull IVF Unit, UK following approval by The 84 
Yorkshire and The Humber NRES ethical committee, UK (approval number 02/03/043). The PCOS 85 
subjects were recruited sequentially in 2015, using the revised 2003 criteria from the Rotterdam 86 
ESHRE/ASRM sponsored PCOS consensus workshop group, indicating PCOS to be present if any 2 out 87 
of 3 criteria were met: menstrual disturbance (oligo or amenorrhoea), clinical and/or biochemical 88 
signs of androgenism or polycystic ovaries on ultrasound (PCOS Consensus Workshop, 2004).  89 
Inclusion criteria were age 20-45 years, BMI ≤35 and undergoing in vitro fertilisation. Patients with 90 
known immunological disease, diabetes, renal or liver insufficiency, acute or chronic infections, or 91 
inflammatory diseases were excluded from the study. No comparative study on which to base formal 92 
power calculations was available; therefore, power and sample size for pilot studies has been 93 
reviewed (Birkett and Day, 1994) that concluded that a minimum of 20 degrees-of-freedom was 94 
required to estimate effect size and variability.  Hence, we planned to recruit 25 patients per group 95 
with an additional 5 patients allowing for drop-outs and covariate adjustment.  A total of 59 women 96 
were recruited into the study, 30 PCOS cases and 29 control subjects matched for age and weight. 97 
 98 
Sample Collection 99 
The subjects fasted from midnight and had a fasting blood sample taken on day 21 of the luteal phase 100 
of the cycle before commencing their IVF treatment. Fasting venous blood samples were collected, 101 
separated by centrifugation at 3500 x g for 15 min at 4°C, and the aliquots stored at -80°oC within 1 102 
hour of collection. Plasma glucose was measured using a Synchron LX20 analyzer (Beckman-Coulter), 103 
and serum insulin was assayed using a competitive chemiluminescent immunoassay performed using 104 
the DPC Immulite 2000 analyzer (Euro/DPC, Llanberis, UK). C reactive protein (CRP) was measured 105 
enzymatically using a Synchron LX20 analyzer (Beckman-Coulter, UK). Estradiol and all thyroid assays 106 
were performed on an Abbott Architect i4000 immunoassay analyser (Abbott Diagnostics Division, 107 
UK). Serum testosterone and androstenedione were measured by liquid chromatography tandem 108 
mass spectrometry (LC/MS/MS; Acquity UPLC-Quattro Premier XE-MS, Waters, Manchester, UK). Sex 109 
hormone binding globulin (SHBG) was measured by an immunometric assay with fluorescence 110 
detection (DPC Immulite 2000 analyzer; upper limit 2.0 nmol/l) . Glycosylated hemoglobin A1c (HbA1c) 111 
measurements were made using ion-exchange chromatography.  112 
 113 
Analysis for PFAAs 114 
Samples were analysed for 13 PFAAs including PFOS, PFOA, perfluorohexane sulfonate (PFHxS), 115 
perfluorononanoic acid (PFNA), and perfluorodecanoic acid (PFDA) (Table 1). 200 µL serum or follicular 116 
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fluid was transferred to a 2 mL Eppendorf tube, followed by addition of the internal standards. 117 
Proteins were precipitated with acetonitrile, centrifuged, filtered (2 µm GHP membrane; Pall, East 118 
Hills, NY, USA), and concentrated under gentle stream of nitrogen. Samples were reconstituted in 119 
5mM ammonium acetate in water prior to analysis via high performance liquid chromatography 120 
tandem mass spectrometry (HPLC-MS/MS) using a Nexera HPLC (Shimadzu Corp., Kyoto, Japan) 121 
coupled to API5500 QTRAP mass spectrometer (Sciex, Melbourne, Australia) with electrospray 122 
ionization (ESI) interface operating in negative mode. Chromatographic separation of the analytes was 123 
achieved with a Gemini C18 column (50x2.0 mm, 4 µm; Phenomenex, Torrance, CA), maintained at 45 124 
°C, with a flow rate of 0.3 mL/min and injection volume of 5 µL. Mobile phases consisted of 125 
methanol:water (1:99, v/v) (A), and methanol:water (95:5, v/v) (B), with 5mM ammonium acetate in 126 
both phases. An isolator column (Phenomenex) was included inline directly after the mobile phase 127 
mixing chamber to delay the elution of solvent-derived background PFAA contamination. Data 128 
acquisition and processing was carried out using Analyst® TF 1.6 and MultiQuantTM software (Sciex). 129 
Further details of reagents, standards, and mass spectrometry settings are provided in the 130 
Supplementary Material.  131 
 132 
Statistics. 133 
Descriptive data are presented as mean ± SD for continuous data and n (%) for categorical data. T-134 
tests were used to compare means where appropriate. A p-value of <0.05 was considered to indicate 135 
statistical significance except for exploratory Pearson correlation coefficient evaluations for regression 136 
modelling development (p<0.1).   137 
 138 
Measured serum PFAA, hormone concentrations, and metabolic markers were assessed for normality 139 
and ln-transformed where appropriate.  Estimated glomerular filtration rate (eGFR) was calculated 140 
using the Modification of Diet in Renal Disease (MDRD) study method (Levey et al., 1999). Insulin 141 
resistance (IR) was calculated from basal glucose and insulin concentration using the homeostasis 142 
model assessment (HOMA) ((Insulin x glucose)/22.5)(Matthews et al., 1985). Free androgen index 143 
(FAI) was calculated as 100 times the ratio of serum testosterone and SHBG concentrations.  A sum 144 
PFAA (∑PFAA) variable by calculated by adding the molar concentrations of the four frequently 145 
detected PFAA compounds (i.e. sum of PFOS, PFOA, PFHxS, PFNA).  146 
 147 
Pairwise Pearson correlation coefficients and significance were examined as an initial step in assessing 148 
potential associations and identifying potential covariates.  Multivariable linear regression was used 149 
to assess predictors for PFAA concentrations and potential associations between measured hormone 150 
concentrations or metabolic endpoints and serum PFAA concentrations.  Tobit regressions were used 151 
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to examine oestradiol concentrations due to left censoring of the data (concentrations below 75 152 
pmol/L were not quantified).  Statistical analyses were conducted using Stata (IC 12.1, Stata Corp., 153 
College Station, TX).   154 
 155 
Results  156 
Cases and controls were similar in age, BMI, and age at menarche (Table 2). Measured hormone 157 
concentrations were not available for all cases and controls (see Table 2).  PCOS cases more frequently 158 
had irregular menstrual cycles (87% vs. 14%, p<0.001).  PCOS cases were more likely to be taking 159 
metformin (47% vs. 0%), and had significantly lower average fasting glucose concentrations than 160 
controls (4.4 nmol/L vs. 4.9 nmol/L, p<0.01), though HbA1c did not differ to controls.   161 
 162 
PCOS cases had higher androgen levels with significantly elevated FAI and androstenedione compared 163 
to controls, though testosterone and oestradiol did not differ. PCOS cases also had lower eGFR on 164 
average than controls (88.3 vs. 97.4 mL/min/ 1.73m-2, p<0.05).  Serum insulin, HOMA-IR and CRP did 165 
not differ between PCOS and controls. 166 
 167 
Detection frequencies and descriptive statistics for serum and follicular fluid PFAA concentrations are 168 
presented in Table 1.  Four PFAAs were detected in all serum and follicular fluid samples:  PFOS, PFOA, 169 
PFHxS, and PFNA, and all were significantly correlated with one another.  Detection frequencies for 170 
PFDA were 76%; and <50% for PFPeA, PFBS, PFHpA and PFUnDA, (49, 7, 17 and 36%, respectively).  In 171 
general, PFOS was present at the highest concentrations, followed by PFOA, PFHxS, and PFNA.  172 
Geometric mean serum concentrations of PFOS were significantly greater in PCOS cases than controls 173 
(Table 1, Figure 1). Other serum PFAAs were not significantly different between PCOS and controls, 174 
and geometric mean follicular fluid concentrations were not different between groups (Table 2), due 175 
to greater variation in measured PFAS concentrations. For the four frequently detected PFAAs, 176 
concentrations in follicular fluid were highly correlated with serum concentrations (R2 > 0.95 for all 177 
four, Figure 2).  The mean ratios of follicular fluid to serum concentrations were 0.59, 0.78, 0.86, and 178 
0.77 for PFOS, PFOA, PFHxS, and PFNA, respectively (Table 1).  179 
 180 
Patients with irregular menstrual cycles (from both PCOS and control groups; n=30, GM: 4.16 ng/mL) 181 
had significantly higher PFOS concentrations than those with regular cycles (n=29, GM 3.25 ng/mL) 182 
(p=0.011, 2-tailed t-test; Figure 3), but the PFOS concentration was not associated with the degree of 183 
irregularity in PCOS patients (not shown). No associations between other PFAA concentrations and 184 
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menstrual cycle regularity were observed. No associations between parity (nulliparous versus 185 
primiparous) and PFAA concentrations were observed (data not shown). 186 
 187 
We examined pair-wise Pearson correlations for the ln-transformed concentrations of the frequently 188 
detected PFAAs and age, BMI, serum albumin, and ln-transformed eGFR (Supplementary Information, 189 
Tables S1 to S3).  No correlations with BMI were observed for any of the PFAAs.  PFOS and PFNA were 190 
negatively correlated with eGFR and positively correlated with serum albumin.  Based on the 191 
correlation matrix, we examined predictors for each PFAA concentration in multivariable regressions 192 
with dependent variables of age, ln-transformed eGFR, serum albumin, and PCOS status.  PFOS was 193 
significantly positively associated with age (approximately 0.1 ng/ml increase per year of age) and 194 
status as a PCOS case vs. control.  PFNA was negatively associated with eGFR.  No other statistically 195 
significant predictors for PFAA concentrations were identified. 196 
 197 
Associations between metabolic endpoints (fasting glucose, serum insulin, HbA1C, and HOMA-IR) and 198 
serum PFAAs were assessed considering potential confounders.  In pairwise correlations, fasting 199 
glucose was positively correlated with age and negatively correlated with serum albumin and status 200 
as a PCOS case; these variables were retained in multivariable regressions examining potential 201 
associations between fasting glucose and ln-transformed PFAA concentrations.  Significant positive 202 
associations were observed between fasting glucose and ln-transformed PFOA (β=0.18, 95% CI 203 
0.01,0.36, p=0.035; i.e. 1.2 ng/mL increase in PFOA for every 1nmol/L increase in glucose) and ln-204 
transformed ∑𝑃𝐹𝐴𝐴 (β=0.18, 95% CI 0.00,0.37, p=0.05; i.e. 1.2 µmol/L increase in ∑PFAA for every 205 
1nmol/L increase in glucose). Serum insulin, HbA1c, and HOMA-IR were all significantly positively 206 
associated with BMI, but no significant associations with any of the PFAAs were observed. These 207 
results were not affected by Inclusion of metformin in use in the analysis or stratification by metformin 208 
use.   209 
 210 
We examined associations between ln-transformed concentrations of each of the four frequently 211 
detected PFAAs and steroid hormone concentrations, SHBG concentrations, and FAI, adjusting for 212 
status as a PCOS case vs. control, as well as for serum albumin concentrations (Table 3).  ∑𝑃𝐹𝐴𝐴 was 213 
assessed in association with hormone concentrations.  Serum testosterone concentrations were 214 
positively associated with ln-transformed PFOA and with ∑𝑃𝐹𝐴𝐴, though not with the degree of 215 
testosterone elevation. SHBG concentrations were significantly positively associated with PFOS and 216 
with ∑𝑃𝐹𝐴𝐴.  No other significant associations between measured steroid hormone levels and serum 217 
PFAA concentrations were observed in adjusted models (Table 3).   218 
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 219 
No significant associations between any of the frequently detected PFAAs and TSH, fT3, or fT4 were 220 
observed.  Both fT3 and fT4 were significantly negatively associated with serum albumin, consistent 221 
with non-specific binding of total T3 and T4 to serum protein (not shown).   222 
 223 
Discussion 224 
The potential effects of PFAAs on reproductive and thyroid hormones and potential influences on 225 
reproductive health are of interest given previous reports linking PFAAs to alterations in endocrine 226 
activity and function(Bach et al., 2016; Coperchini et al., 2017).  The profile of PCOS also includes 227 
alterations in reproductive hormones; thus, this population might represent a sensitive subpopulation 228 
for chemical exposures that also influence hormone concentrations.  229 
 230 
The four frequently detected PFAAs were correlated with each other in this study, consistent with 231 
previous reports (Calafat et al., 2007; Ye et al., 2017).  Concentrations in follicular fluid of each PFAA 232 
were strongly associated with the corresponding serum concentrations, with average ratios ranging 233 
from approximately .59 to .86 for the four frequently detected PFAAs (Table 1).  These ratios are 234 
similar to those reported by McCoy et al. (2017) (McCoy et al., 2017) for PFOA, PFHxs, and PFNA, but 235 
somewhat lower than the value reported for PFOS (0.59 in the current study vs. 0.82 in McCoy et al. 236 
2017).  The lower concentrations in follicular fluid relative to serum might reflect a lower total protein 237 
concentration in follicular fluid relative to serum (Leroy et al., 2004), which is pertinent because PFAAs 238 
are known to be protein bound (Andersen et al., 2008; Bischel et al., 2010).  The high correlations 239 
between PFAA concentrations in follicular fluid and serum suggest that measures of PFAAs in serum 240 
likely are good surrogates for examining potential dose-effect relationships on the ovary. 241 
 242 
The assessment of associations between PFAA levels and sex steroid hormones resulted in limited 243 
findings of a positive association between testosterone and PFOA and the molar sum of PFAAs after 244 
adjusting for serum albumin concentrations and PCOS case status; no significant findings remained 245 
after adjustment for the other hormone-PFAA combinations (Table 3). When the data were restricted 246 
to PCOS cases alone there was no linear relationship of PFOS to increased testosterone.  This may be 247 
due to a combination of the small sample size (n= 27 PCOS cases with measured testosterone) and the 248 
high degree of variation in testosterone levels in the PCOS cases. In a recent systematic review, Bach 249 
et al. (2016) reported that associations between reproductive hormone levels and PFAA exposures 250 
was mixed (Bach et al., 2016).   251 
 252 
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TSH, free T3, and free T4 were not associated with any of the frequently detected PFAAs or the sum 253 
of these PFAAs in this study.   We did observe a negative correlation between serum albumin and free 254 
T4 and free T3.  Previous studies have reported mixed results regarding associations between PFAAs 255 
and thyroid hormones.  Crawford et al. (2017) in a study of women without infertility found no 256 
associations between TSH and PFAAs, and reported a positive association between free T4 and PFNA 257 
(Crawford et al., 2017).  Lin et al. (2013) found a similar relationship between free T4 and PFNA in 258 
adolescents and young adults from the NHANES survey (Lin et al., 2013).  Chan et al. 2011 found no 259 
associations between serum PFAA concentrations and hypothyroxinemia in 974 pregnant women 260 
(Chan et al., 2011).  Lewis et al. (2015) found a positive association between free T4 and serum 261 
concentrations of all four PFAAs considered here in women of reproductive age in the NHANES 2011-262 
2012 survey, but other thyroid hormone concentrations were not associated with PFAAs in women of 263 
reproductive age (Lewis et al., 2015). Overall, studies have reported a mixed pattern of associations 264 
between PFAAs and thyroid hormone concentrations (de Cock et al., 2014; Jain, 2013; Ji et al., 2012; 265 
Kato et al., 2016; Li et al., 2017a; Shah-Kulkarni et al., 2016; Tsai et al., 2017).  266 
 267 
PCOS cases had higher geometric mean concentrations of PFOS than controls, but concentrations of 268 
other PFAAs were similar between cases and controls.  Vagi et al. (2014) found elevated PFOS and 269 
PFOA concentrations in another study of PCOS cases relative to controls (Vagi et al., 2014).  The current 270 
study also found an association of PFOS concentrations with menstrual irregularity, similar to one 271 
previous study (Lyngso et al., 2014). Menstruation may be an important elimination pathway for 272 
PFAAs, and has been hypothesized to be responsible for lower PFAA concentrations in females 273 
compared to males (Lorber et al., 2015; Wong et al., 2014) and in post-menopausal women (Lorber et 274 
al., 2015). In PCOS women who may suffer from oligomenorrhea or amenorrhea, and thus menstruate 275 
less frequently than controls, the same exposure dose could result in higher serum PFAAs 276 
concentrations (Vagi et al., 2014). However, for the PCOS women, there was no significant difference 277 
in PFOS concentration between cases with cycles greater than or less than 40 days. Similarly, in this 278 
dataset, PFAAs other than PFOS were not significantly associated with menstrual cycle regularity.   279 
 280 
In addition, we found that PCOS cases had significantly lower eGFR than controls. Evidence from the 281 
literature suggestd this may be due to inflammation and reflected in a higher CRP (Gozukara et al., 282 
2015); however, in our study, CRP did not differ between PCOS and controls. . Renal elimination is 283 
another pathway for elimination of PFAA compounds (Han et al., 2012; Verner et al., 2015).  Thus, 284 
lower eGFR for PCOS cases may result in higher serum PFAA concentrations for the same external 285 
exposure level, which was observed for PFOS, and potentially compounded by menstrual irregularity, 286 
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thereby reducing PFAA elimination.  Previous cross-sectional studies considered the possibility that 287 
PFAAs may negatively impact renal function, resulting in decreased eGFR (Kataria et al., 2015; Watkins 288 
et al., 2013).  In this dataset, PFOS and PFNA were inversely correlated with eGFR (p<0.05); PFOA and 289 
PFHxS were not significantly correlated with eGFR.  Thus, decreased eGFR in PCOS cases may result in 290 
some increase in serum concentrations of selected PFAA compounds in these cases compared to 291 
controls, but this relationship may be compound-specific.   292 
 293 
Recent temporal studies report decreasing serum concentrations of PFOS and PFOA, and a 294 
corresponding increase of alternative PFAAs used as replacement chemicals, likely due to action from 295 
manufacturers and legislators to phase out PFOS and PFOA (Land et al., 2015; US EPA, 2015). In 296 
comparison with the biomonitoring literature, PFOS concentrations in this UK cohort were lower than 297 
most previously reported pregnancy cohorts globally (reviewed in (Miralles-Marco and Harrad, 2015)), 298 
whereas PFOA and PFHxS were higher (Table S4).  299 
 300 
The strengths of the study lie in the age and BMI matched population, with measurement of a range 301 
of hormone and metabolic markers.  In addition, PCOS patients may represent a sensitive 302 
subpopulation for effects of endocrine active substances. The study was limited by the small sample 303 
size and by missing data for some hormone measurements.  A relatively large number of statistical 304 
evaluations were conducted (approximately 12 outcome measures by four PFAAs and the molar sum 305 
of the four PFAAs, plus assessments of predictors for PFAA concentrations), suggesting that some 306 
findings might be expected to be observed by chance.   307 
 308 
We found high correlations between PFAAs in follicular fluid and serum, supporting the use of serum 309 
as a relevant matrix for biomonitoring for PFAAs for assessment of potential ovarian responses.  310 
Concentrations of PFOS, but not other PFAAs, were higher in the PCOS cases than in controls in this 311 
study. We found evidence of a positive associations between PFOA concentrations and summed PFAA 312 
concentrations and testosterone, and between PFOS and summed PFAAs and SHBG concentrations in 313 
the PCOS cases and controls in this study.  The relationships to summed PFAAs appear to be largely 314 
driven by the contributions from the individual significant predictors; that is, the relationships to 315 
summed PFAAs are not stronger in magnitude or significance than the relationships to PFOA or PFOS.  316 
Fasting glucose was positively associated with PFOA concentrations and with summed PFAAs, but not 317 
other PFAAs.  Again, the relationship with summed PFAAs appears to be largely due to the specific 318 
association with PFOA.   319 
 320 
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We identified a number of factors that should be considered in the evaluation of PFAA concentrations 321 
and potential associations with reproductive outcomes, steroid hormone concentrations, and related 322 
endpoints.  Characteristics such as menstrual irregularity, parity, eGFR, and serum albumin levels may 323 
influence serum PFAA concentrations due to elimination mechanisms or physical/chemical properties 324 
of these compounds, and some of these characteristics may also be altered in populations under study 325 
for reproductive outcomes.  In addition, serum albumin concentrations can influence both measured 326 
serum hormone concentrations and serum concentrations of PFAAs.  Non-covalent binding of sex 327 
steroid hormones to serum protein is recognized as a factor affecting transport and metabolism of 328 
these hormones (Egloff et al., 1981; Pardridge, 1986), and we observed positive associations between 329 
serum albumin concentrations and the measured levels of the sex steroid hormones.  Similarly, T3, 330 
and T4 are protein bound in serum (Koulouri et al., 2013).  We observed a negative correlation 331 
between free T3 and free T4 and albumin in this dataset (Table S2), consistent with this protein 332 
binding. PFAAs are also protein-bound in serum.  These interrelationships suggest that characteristics 333 
that influence PFAA elimination or serum concentrations, and which may also be associated with 334 
outcome variables, be carefully considered as covariates in future assessments of associations 335 
between hormone concentrations, reproductive outcomes, and serum PFAAs.   336 
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Tables and Figures 
Table 1. Summary of PFAA serum concentrations in PCOS case-control study  (ng/mL) 
 
  Detection 
frequency, n (%) 
Geometric Mean Range Average 
ratio 
LOR 




















0.57 0.41 0.2-1.79 0.1-1.43 0.77 0.2 0.1 




- 0.2 0.2 
PFPeA 29 (49) 0 - - <LOR-
2.02 
- - 0.5 0.3 
PFUnDA 21 (36) 0 - - <LOR-
0.47 
- - 0.2 0.7 




- 0.1 0.1 




- 0.2 0.2 
PFBA 0 0 - - - - - 0.5 0.2 
PFHxA 0 0 - - - - - 0.5 0.1 
PFDS 0 0 - - - - - 0.5 0.1 
PFDoDA 0 0 - - - - - 0.5 0.4 
FF, follicular fluid; LOR, limit of reporting; PFOS, perfluorooctane sulfonate; PFOA, perfluorooctanoic acid; 
PFHxS, perfluorohexane sulfonate; PFNA, perfluorononanoic acid; PFDA, perfluorodecanoic acid; PFPeA, 
perfluoropentanoic acid; PFUnDA, perfluoroundecanoic acid; PFHpA, perfluoroheptanoic acid; PFBS, 
perfluorobutanesulfonate; PFBA, perfluorobutanoic acid; PFHxA, perfluorohexanoic acid; PFDS, 
Perfluorodecane sulfonate; PFDoDA, perfluorododecanoic acid 
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Table 2. Demographics, hormone and biochemistry endpoints, and serum and follicular PFAA concentrations for PCOS patients and controls.   
 
Control (n=28) PCOS (n=31)  
Mean ± SD Mean ± SD 
Age (years) 32.9 ± 4.6 30.7 ± 4.6 
Body mass index (kg/m2) 25.6 ± 3.7 25.9 ± 3.8 
Menarche (years) 13.1 ± 1.8 12.8 ± 1.3 
Irregular menstrual cycle (%) 14% 87%*** 
Nulliparous (%) 97% 83% 
Insulin (μIU/ml) 7.9 ± 4.1 7.9 ± 4.6 
Fasting glucose (nmol/L) 4.9 ± 0.4 4.4 ± 0.8** 
HbA1C (mmol/mol) 30.9 ± 6.5 (n=27) 31.8 ± 3.0 (n=28) 
HOMA-IR 1.8 ± 1.0 1.9 ± 1.6 
Metformin use (%) 0% 47%*** 
SHBG (nmol/L) 104.2 ± 80.3 (n=28) 71.7 ± 62.2 (n=28) 
Testosterone (nmol/L) 0.85 ± 0.56 (n=27) 1.04  ± 0.37 (n=27) 
Free androgen index (FAI) 1.44 ± 1.47 (n=27) 3.32  ± 4.08 (n=27)* 
Estradiol (pmol/L) 398.0 ± 423.4 (n=27) 259.1 ± 276.0 (n=26) 
Androstenedione (nmol/L) 2.7 ± 1.4 (n=23) 4.0 ± 1.5 (n=24)** 
TSH (mU/L) 2.3 ± 1.0 (n=27) 2.0 (0.8) (n=28) 
Free T3 (pmol/L) 4.8 ± 0.7 (n=26) 4.8 ± 0.7 (n=24) 
Free T4 (pmol/L) 11.2 ± 1.3 (n=26) 11.4 ± 2.2 (n=24) 
eGFR (mL/min 1.73m-2) 97.4 ± 18.9 (n=28) 88.3 ± 10.1 (n=28)* 
C Reactive Protein (mg L-1) 2.34 ± 2.34 (n=27) 2.77 ± 2.57 (n=28) 
Albumin (g/L) 40.1 ± 2.9 (n=28) 40.6 ± 3.1 (n=28) 
Seruma   
  PFOS, (ng/mL) 3.1 (2.6-3.6) 3.9 (3.4-4.4)* 
  PFOA, (ng/mL) 2.4 (1.9-2.9) 2.4 (2.0-2.9) 
  PFHxS, (ng/mL) 0.9 (0.8-1.2) 1.1 (0.9-1.4) 
  PFNA, (ng/mL) 0.5 (0.4-0.6) 0.6 (0.5-0.7) 
Follicular fluida   
  PFOS, (ng/mL) 1.8 (1.6-2.1) 2.2 (1.9-2.5) 
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  PFOA, (ng/mL) 1.9 (1.6-2.3) 1.7 (1.4-2.1) 
  PFHxS, (ng/mL) 0.8 (0.6-1.0) 0.9 (0.7-1.2) 
  PFNA, (ng/mL) 0.4 (0.3-0.5) 0.4 (0.3-0.5) 
*p<0.05, **p<0.01, ***p<0.001; a Geometric mean (95% CI) 
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Table 3:  Associations of measured steroid hormone concentrations and related endpoints with PFAA concentrations, adjusted for serum albumin and PCOS case 
status.  Bolded associations are significant at p<0.05. 
 


















0.57 (0.61)  
0.356 
-22.63 (115.46)  
0.845 






0.96 (0.52)  
0.071 
95.78 (150.78)  
0.528 






0.68 (0.44)  
0.131 
86.94 (122.72)  
0.482 
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0.97 (0.57)  
0.094 










1.11 (0.63)  
0.084 












Figure 1. Plot of serum concentration (ng/mL, n=59) of PFAAs with detection frequencies >50%. Box 
indicates interquartile range, whiskers indicate 5th% and 95th %, horizontal line indicates median. 
Significantly different geometric means (p<0.05) denoted by asterisk.  
  




Figure 2. Correlation of PFOS (A), PFOA (B), PFHxS (C) and PFNA (D) in serum and follicular fluid. 
Shaded area represents 95% confidence interval of regression line forced through the origin (red); R2 









Figure 3: Perfluorooctane sulfonate (PFOS) concentration in women with regular versus irregular 
menstrual cycles (p<0.05 for difference of means). Horizontal line represents the geometric mean. 
 
 
 
